{"filings":[{"id":527358,"accession_number":"0001323885-26-000025","cik":1323885,"company_name":"AtriCure, Inc.","ticker":"ATRC","form_type":"8-K","filed_at":"2026-05-19T20:21:39+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"AtriCure shareholders approve share increases for 2023 Stock Incentive Plan and 2018 ESPP","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Shareholders approved amendment to 2023 Stock Incentive Plan, increasing authorized shares from 4.5M to 6M.","Shareholders approved amendment to 2018 Employee Stock Purchase Plan, increasing authorized shares by 750,000.","All nine director nominees elected; Deloitte ratified as auditor; say-on-pay approved with over 40M votes.","Stock plan amendment passed with ~41M for vs 1.1M against; broker non-votes of 3.8M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":1427568936.5978143,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":92090,"accession_number":"0001323885-26-000020","cik":1323885,"company_name":"AtriCure, Inc.","ticker":"ATRC","form_type":"8-K/A","filed_at":"2026-05-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"AtriCure Q1 revenue $141.2M (+14.3%); corrects FY2026 guidance to rev $600-610M, adj EBITDA $80-82M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 revenue $141.2M (+14.3% YoY); net income $0.1M, breakeven EPS.","U.S. rev growth 14.9% driven by cryoSPHERE MAX, AtriClip FLEX-Mini, EnCompass clamp.","Adjusted EBITDA $17.1M, up 95% YoY; gross margin 77.4% (+246 bps).","Corrected FY2026 guidance: revenue $600-610M, adj EBITDA $80-82M, adj EPS $0.09-0.15, net EPS $0.00-0.04.","International revenue $25.0M (+11.5% as reported; +3.3% constant currency)."],"consensus_eps_estimate":null,"consensus_eps_actual":0.0,"consensus_revenue_estimate":null,"consensus_revenue_actual":141249000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1427568936.5978143,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":92091,"accession_number":"0001323885-26-000018","cik":1323885,"company_name":"AtriCure, Inc.","ticker":"ATRC","form_type":"8-K","filed_at":"2026-05-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"AtriCure Q1 2026 revenue $141.2M (+14.3%); net income $0.1M; adj. EBITDA $17.1M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Worldwide revenue $141.2M (+14.3% YoY); U.S. $116.2M (+14.9%), international $25.0M (+11.5%).","Gross margin 77.4% (+246 bps); income from operations $0.5M vs loss of $6.0M in Q1 2025.","Net income $0.1M; EPS breakeven at $0.00 (vs net loss $0.14 in Q1 2025).","Adjusted EBITDA $17.1M, up 95% from $8.8M in Q1 2025.","No GAAP-to-non-GAAP reconciling items; adjusted EPS also $0.00."],"consensus_eps_estimate":null,"consensus_eps_actual":0.0,"consensus_revenue_estimate":null,"consensus_revenue_actual":141249000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1427568936.5978143,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":102649,"accession_number":"0001323885-26-000005","cik":1323885,"company_name":"AtriCure, Inc.","ticker":"ATRC","form_type":"8-K","filed_at":"2026-02-17T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"AtriCure Q4 revenue $140.5M (+13.1% YoY); guides FY26 revenue $600-610M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2025 revenue $140.5M (+13.1% YoY); net income $1.8M ($0.04 EPS) vs net loss $0.33 per share in Q4 2024.","FY 2025 revenue $534.5M (+14.9% YoY); net loss $11.4M ($0.24 loss per share) improved from $0.95 loss per share in 2024.","FY 2025 adjusted EBITDA $61.8M (+98% vs $31.1M in 2024); Q4 adj. EBITDA $19.9M vs $12.7M.","FY 2026 guidance: revenue ~$600-610M (12-14% growth); adj. EBITDA $80-82M; positive net income; adj. EPS $0.09-0.15.","U.S. revenue $435.4M (+13.7%); international $99.2M (+20.2%); growth driven by cryoSPHERE MAX, AtriClip FLEX-Mini, EnCompass clamp."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.24,"consensus_revenue_estimate":null,"consensus_revenue_actual":534528000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1427568936.5978143,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":102648,"accession_number":"0001193125-26-009814","cik":1323885,"company_name":"AtriCure, Inc.","ticker":"ATRC","form_type":"8-K","filed_at":"2026-01-12T23:59:59+00:00","items":["1.01","2.02","2.03","9.01"],"status":"ready","headline":"AtriCure reports preliminary Q4 revenue $140.5M (+13%), FY 2025 $534.5M (+15%); guides 2026 revenue ~$600-610M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2025 revenue $140.5M (+13% YoY); US $114.3M (+13%), intl $26.2M (+15% as reported).","FY 2025 revenue $534.5M (+15% YoY); adj. EBITDA $57-59M; adj. loss per share $0.18-0.21.","Ended 2025 with $167M cash; expects positive cash flow and net income in 2026.","2026 revenue guidance $600-610M (+12-14%); adj. EBITDA $80-82M.","Amended credit facility extended 3 years, reduced interest rate, removed minimum utilization covenant."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.24,"consensus_revenue_estimate":null,"consensus_revenue_actual":534528000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1427568936.5978143,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":118884,"accession_number":"0001323885-25-000098","cik":1323885,"company_name":"AtriCure, Inc.","ticker":"ATRC","form_type":"8-K","filed_at":"2025-10-29T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"AtriCure Q3 revenue +15.8% to $134.3M, net loss narrows to $0.3M; raises 2025 outlook","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue of $134.3M (+15.8% YoY); U.S. $109.3M (+14.5%), international $25.0M (+22.0%).","Net loss of $0.3M ($0.01 diluted EPS) improves $7.6M YoY; adjusted EBITDA $17.8M (+$9.9M).","Gross margin 75.5% (+59 bps) on favorable product mix; operating income $0.2M vs loss of $7.4M.","Company raises full-year 2025 financial outlook (specific guidance numbers not disclosed in press release)."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.28,"consensus_revenue_estimate":null,"consensus_revenue_actual":394028000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1427568936.5978143,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":118883,"accession_number":"0001323885-25-000101","cik":1323885,"company_name":"AtriCure, Inc.","ticker":"ATRC","form_type":"8-K/A","filed_at":"2025-10-29T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"AtriCure Q3 revenue $134.3M (+15.8% YoY); net loss narrows to $0.3M; raises FY2025 outlook","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $134.3M, +15.8% YoY (+15.1% constant currency); US $109.3M (+14.5%), intl $25.0M (+22.0%).","Net loss $0.3M vs $7.9M loss in Q3 2024; GAAP EPS loss $0.01 vs $0.17; adjusted EBITDA $17.8M (+$9.9M).","Generated $30.1M cash in Q3, $25.1M YTD; raised full-year 2025 financial outlook.","Key product drivers: AtriClip FLEX-Mini, EnCompass clamp, cryoSPHERE MAX probe for pain management.","Gross margin 75.5%, up 59 bps YoY on favorable product mix."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.28,"consensus_revenue_estimate":null,"consensus_revenue_actual":394028000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1427568936.5978143,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":135429,"accession_number":"0001323885-25-000092","cik":1323885,"company_name":"AtriCure, Inc.","ticker":"ATRC","form_type":"8-K","filed_at":"2025-07-29T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"AtriCure Q2 revenue up 17%; net loss narrows; raises 2025 outlook","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Worldwide revenue $136.1M (+17.1% YoY); U.S. $110.6M (+15.7%), Int'l $25.6M (+23.3%).","Net loss $6.2M, improved $1.8M YoY; adjusted EBITDA $15.4M, up $7.6M YoY.","Basic/diluted EPS loss $0.13 vs $0.17; adjusted EPS loss $0.02 vs $0.17.","Completed enrollment of 6,500 patients in the LeAAPS trial.","Company raised full-year 2025 financial outlook."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.27,"consensus_revenue_estimate":null,"consensus_revenue_actual":259759000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.78,"calibrated_materiality_score":0.78,"market_cap_usd":1427568936.5978143,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":152416,"accession_number":"0001323885-25-000050","cik":1323885,"company_name":"AtriCure, Inc.","ticker":"ATRC","form_type":"8-K","filed_at":"2025-05-20T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"AtriCure shareholders approve 1.7M share increase in 2023 Stock Incentive Plan at annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Shareholders approved amendment to 2023 Stock Incentive Plan, increasing shares from 2.8M to 4.5M.","All 9 director nominees elected; auditor Deloitte ratified; say-on-pay passed with ~78% support.","Advisory vote on frequency of say-on-pay resulted in one-year frequency; board adopts annual votes.","The plan amendment increases share pool by 1.7M shares (60.7% increase)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":1427568936.5978143,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":152415,"accession_number":"0001323885-25-000041","cik":1323885,"company_name":"AtriCure, Inc.","ticker":"ATRC","form_type":"8-K","filed_at":"2025-04-29T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"AtriCure Q1 revenue $123.6M (+13.6% YoY); net loss improves to $6.7M from $13.2M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $123.6M (+13.6% YoY; +14.1% constant currency); U.S. $101.1M (+12.1%), International $22.5M (+20.8%).","Net loss $6.7M ($0.14 per share) improved from $13.2M ($0.28 per share) a year ago.","Adjusted EBITDA $8.8M, up from $2.8M in Q1 2024; gross margin 74.9% (+27 bps).","Growth driven by EnCompass clamp, cryoSPHERE MAX probes, AtriClip Flex-Mini device launches."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.14,"consensus_revenue_estimate":null,"consensus_revenue_actual":123620000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1427568936.5978143,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":171247,"accession_number":"0001323885-25-000033","cik":1323885,"company_name":"AtriCure, Inc.","ticker":"ATRC","form_type":"8-K","filed_at":"2025-03-26T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"AtriCure holds 2025 Investor Day; presentation details not provided in filing excerpt","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Investor Day held March 26, 2025 at Mason, OH headquarters from 1-4 p.m. ET.","CEO Michael Carrel presented; no specific financial targets or guidance changes cited.","Exhibit 99.1 presentation file is referenced but only a title fragment was included in the user input."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":1427568936.5978143,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":171246,"accession_number":"0001323885-25-000005","cik":1323885,"company_name":"AtriCure, Inc.","ticker":"ATRC","form_type":"8-K","filed_at":"2025-02-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"AtriCure Q4 revenue $124.3M (+16.6% YoY); guides FY25 rev $517-527M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $124.3M (+16.6%); full year revenue $465.3M (+16.5%).","Q4 GAAP net loss $0.33/sh; adj. loss $0.08/sh; adj. EBITDA positive $12.7M.","Full year 2024 adj. EBITDA $31.1M (vs $19.4M in 2023); adj. loss $0.67/sh (vs $0.75).","Launched cryoSPHERE+, cryoSPHERE MAX, AtriClip FLEX-Mini in US, EnCompass clamp in Europe.","FY2025 guidance: rev $517-527M; adj. EBITDA $42-44M; adj. loss $0.57-0.64/sh."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.95,"consensus_revenue_estimate":null,"consensus_revenue_actual":465307000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1427568936.5978143,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":171245,"accession_number":"0001323885-25-000002","cik":1323885,"company_name":"AtriCure, Inc.","ticker":"ATRC","form_type":"8-K","filed_at":"2025-01-13T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"AtriCure reports preliminary Q4 revenue $124.3M (+17%); guides 2025 revenue $517-527M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Preliminary Q4 2024 revenue $124.3M (+17% YoY as reported and constant currency).","U.S. revenue $101.6M (+14%), international $22.7M (+28%) in Q4.","FY2024 revenue $465.3M (+17%); expects adj. EBITDA $26M-$29M and adj. EPS loss $0.74-$0.80.","2025 guidance: revenue $517M-$527M, adj. EBITDA $40M-$44M, modest cash flow generation.","Analyst & Investor Day scheduled for March 26, 2025 at Mason, Ohio headquarters."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.95,"consensus_revenue_estimate":null,"consensus_revenue_actual":465307000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1427568936.5978143,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":188223,"accession_number":"0001323885-24-000115","cik":1323885,"company_name":"AtriCure, Inc.","ticker":"ATRC","form_type":"8-K","filed_at":"2024-10-29T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"AtriCure Q3 2024: revenue $115.9M (+17.9%), loss $0.17/sh, positive cash flow $16.3M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Worldwide revenue $115.9M, up 17.9% YoY; U.S. $95.5M (+16.8%), Intl $20.5M (+23.3%).","Net loss per share $0.17 vs $0.20 YoY; adjusted EBITDA $7.9M, up $3.2M from Q3 2023.","Gross margin 74.9%, down 27 bps YoY due to unfavorable product/geographic mix.","Generated $16.3M cash flow from operations in the quarter.","Launched new products; growth driven by open ablation, appendage management, and pain management."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.62,"consensus_revenue_estimate":null,"consensus_revenue_actual":341030000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1427568936.5978143,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":204709,"accession_number":"0001323885-24-000104","cik":1323885,"company_name":"AtriCure, Inc.","ticker":"ATRC","form_type":"8-K","filed_at":"2024-07-30T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"AtriCure Q2 2024 revenue $116.3M (+15.2% YoY); net loss $0.17/share","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Worldwide revenue $116.3M, up 15.2% YoY (15.4% constant currency); U.S. $95.5M (+12.5%), international $20.7M (+29.4%).","Gross margin 74.7%, down 168 bps YoY due to mix and product costs; operating loss $7.2M vs $4.1M loss.","Net loss per share $0.17 vs $0.11; adjusted EBITDA $7.8M, down $0.2M vs Q2 2023.","Generated positive cash flow of $8.1M during the quarter.","CEO cited strong growth from pain management and AtriClip franchises; advancing LeAAPS trial and new product launches."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.45,"consensus_revenue_estimate":null,"consensus_revenue_actual":225120000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1427568936.5978143,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":221559,"accession_number":"0001323885-24-000068","cik":1323885,"company_name":"AtriCure, Inc.","ticker":"ATRC","form_type":"8-K","filed_at":"2024-05-14T23:59:59+00:00","items":["5.02","5.03","5.07","9.01"],"status":"ready","headline":"AtriCure shareholders approve increase in authorized shares under 2023 Stock Incentive Plan to 2.8M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Shareholders approved amendment to 2023 Stock Incentive Plan, increasing shares from 1,000,000 to 2,800,000.","Shareholders approved amendment to certificate of incorporation to limit officer liability under Delaware law.","Nine director nominees elected; Deloitte ratified as auditor; say-on-pay approved with 35.6M for vs 6.5M against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":1427568936.5978143,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":221558,"accession_number":"0001323885-24-000060","cik":1323885,"company_name":"AtriCure, Inc.","ticker":"ATRC","form_type":"8-K","filed_at":"2024-05-01T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"AtriCure Q1 revenue $108.9M (+16.4% YoY); net loss per share $0.28","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Worldwide revenue $108.9M, up 16.4% YoY (16.3% constant currency); U.S. revenue $90.2M (+15.4%), international $18.6M (+21.5%).","GAAP net loss $0.28 per share vs $0.14 loss in Q1 2023; operating loss $10.9M (includes $4M prior-year legal settlement gain).","Adjusted EBITDA $2.8M vs $1.9M a year ago; adjusted loss per share $0.25 vs $0.23.","Gross margin 74.7%, up 21 bps YoY on favorable product/geographic mix.","CEO cites strong start with growth across all franchises; new product launches and clinical research ahead."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.28,"consensus_revenue_estimate":null,"consensus_revenue_actual":108851000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1427568936.5978143,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":241095,"accession_number":"0001323885-24-000020","cik":1323885,"company_name":"AtriCure, Inc.","ticker":"ATRC","form_type":"8-K/A","filed_at":"2024-02-27T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"AtriCure amends 8-K to add director Shlomi Nachman to two board committees","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Shlomi Nachman elected to Board on Jan 4, 2024, as previously reported.","Effective Feb 22, 2024, Nachman appointed to Strategy Committee and Compliance, Quality and Risk Committee.","Amendment filed to disclose committee assignments not included in original 8-K."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":1427568936.5978143,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}